biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by Hobberson Jan 08, 2014 2:09pm

163 Views

Post# 22070545

RE:Competition?

Kayacker,

Thanks for the response.

It might have helped if BTI and the work they're doing was included in that press release. Roche gets the publicity along with a mention of Lilly, Merck and Johnson and Johnson, and BTI gets the cold shoulder. Hard to understand that one.

I own shares in ISIS, a US antisense and RNAi biotech company, and noticed they are getting involved with Roche to increase penetration of drugs into the brain. Good news for ISIS as they are on quite a roll, though I would have liked to see BTI involved with them instead of Roach.

Bullboard Posts

The investment impact of the U.S. 25% tariff on Canadian imports